Download PDF
Dtsch Med Wochenschr 2008; 133(43): 2233-2237
DOI: 10.1055/s-0028-1091266
Arzneimittel & Pharmakotherapie | Review article
Diabetologie
© Georg Thieme Verlag KG Stuttgart · New York

Sitagliptin

DPP-4-Inhibitoren als sinnvolle Erweiterung der oralen Diabetestherapie?Sitagliptin DPP-4 Inhibitors as expedient extension of oral diabetes treatment?J. Matthes1 , M. Faust2
  • 1Institut für Pharmakologie, Universität zu Köln
  • 2Klinik II und Poliklinik für Innere Medizin, Uniklinik Köln
Further Information

Publication History

eingereicht: 6.3.2008

akzeptiert: 23.7.2008

Publication Date:
15 October 2008 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

antidiabetische Therapie - Diabetes mellitus - GLP-1 - Inkretin

Keywords

antidiabetic therapy - diabetes mellitus - GLP-1 - incretin

Literatur

  • 1 Ahmad S R, Swan J. Exenatide and rare adverse events.  N Engl J Med. 2008;  358 1970-1971
    Google Scholar
  • 2 Ahrén B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.  Horm Metab Res. 2004;  36 867-876
    Google Scholar
  • 3 Amori R E, Lau J, Pittas A G. Efficacy and Safety of Incretin Therapy in Type 2 Diabetes. Systematic Review and Meta-analysis.  JAMA. 2007;  298 194-206
    Google Scholar
  • 4 Aronoff S L, Berkowitz K, Shreiner B, Want L. Glukose metabolism and regulation: beyond insulin and Glukagon.  Diabetes Spectr. 2004;  17 183-190
    Google Scholar
  • 5 Berthold H K, Gouni-Berthold I, Bestehorn K, Böhm M, Krone W. Kardiovaskuläre Risikofaktoren bei Typ-2-Diabetikern in Deutschland – ein Versorgungsparadox.  Dtsch Arztebl. 2007;  104 A861-A867
    Google Scholar
  • 6 Buse J B, Henry R R, Han J. et al . Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.  Diabetes Care. 2004;  27 2628-2635
    Google Scholar
  • 7 Deacon C F, Holst J J. Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.  Int J Biochem Cell Biol. 2006;  38 831-844
    Google Scholar
  • 8 Elahi D, McAloon-Dyke M, Fukagawa N K. et al . The insulinotropic actions of Glukose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7 – 37) in normal and diabetic subjects.  Regul Pept. 1994;  51 63-74
    Google Scholar
  • 9 He Y L, Wang Y, Bullock J M. et al . Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT.  J Clin Pharmacol. 2007;  47 633-641
    Google Scholar
  • 10 Henness S, Keam S J. Vildagliptin.  Drugs. 2006;  66 1989-2001
    Google Scholar
  • 11 Herman G A, Bergman A, Stevens C. et al . Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma Glukose levels following an oral Glukose tolerance test in patients with type 2 diabetes.  J Clin Endocrinol Metab. 2006;  91 4612-4619
    Google Scholar
  • 12 Kolligs F, Fehmann H C, Goke R, Goke B. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9 – 39) amide.  Diabetes. 1995;  44 16-19
    Google Scholar
  • 13 Lewis J T, Dayanandan B, Habener J F, Kieffer T J. Glukose-dependent insulinotropic polypeptide confers early phase insulin release to oral Glukose in rats: demonstration by a receptor antagonist.  Endocrinology. 2000;  141 3710-3716
    Google Scholar
  • 14 Lyseng-Williamson K A. Sitagliptin.  Drugs. 2007;  67 587-597
    Google Scholar
  • 15 Mojsov S, Weir G C, Habener J F. Insulinotropin: glucagon-like peptide I (7 – 37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.  J Clin Invest. 1987;  79 616-619
    Google Scholar
  • 16 Nathan D M. Finding new treatments for Diabetes – How many, how fast … how good?.  N Engl J Med. 2007;  356 437-440
    Google Scholar
  • 17 Nauck M A, Heimesaat M M, Orskov C, Holst J J, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7 – 36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.  J Clin Invest. 1993;  91 301-307
    Google Scholar
  • 18 Nauck M A, Homberger E, Siegel E G. et al . Incretin effects of increasing Glukose loads in man calculated from venous insulin and C-peptide responses.  J Clin Endocrinol Metab. 1986;  63 492-498
    Google Scholar
  • 19 Nauck M A, Meininger G, Sheng D, Terranella L, Stein P P. Sitagliptin Study 024 Group . Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.  Diabetes Obes Metab. 2007;  9 194-205
    Google Scholar
  • 20 Nielsen L L. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes.  Drug Discov Today. 2005;  10 703-710
    Google Scholar
  • 21 Orskov C, Holst J J, Knuhtsen S, Baldissera F G, Poulsen S S, Nielsen O V. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas.  Endocrinology. 1986;  119 1467-1475
    Google Scholar
  • 22 Pratley R E, Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.  Curr Med Res Opin. 2007;  23 919-931
    Google Scholar
  • 23 Reuter H, Erdmann E. Exenatid – ein Inkretin-Mimetikum zur Behandlung des Diabetes mellitus Typ 2.  Dtsch Med Wochenschr. 2007;  132 571-574
    Google Scholar
  • 24 Scrocchi L A, Brown T J, MacLusky N. et al . Glukose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.  Nat Med. 1996;  2 1254-1258
    Google Scholar
  • 25 Toft-Nielsen M B, Damholt M B, Madsbad S. et al . Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.  J Clin Endocrinol Metab. 2001;  86 3717-3723
    Google Scholar
  • 26 Prospective Diabetes Study (UKPDS) Group . UK -- Intensive blood-Glukose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).  Lancet. 1998;  352 837-853
    Google Scholar

Dr. Jan Matthes

Institut für Pharmakologie, Universität zu Köln

Gleueler Straße 24

50931 Köln

Phone: 0221/4785-674

Fax: 0221/4785-022

Email: jan.matthes@uni-koeln.de